Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

132 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Development of PI3K inhibitors: lessons learned from early clinical trials.
Rodon J, Dienstmann R, Serra V, Tabernero J. Rodon J, et al. Nat Rev Clin Oncol. 2013 Mar;10(3):143-53. doi: 10.1038/nrclinonc.2013.10. Epub 2013 Feb 12. Nat Rev Clin Oncol. 2013. PMID: 23400000 Review.
First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma.
Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, Lee EQ, Rodon J. Wen PY, et al. Among authors: rodon j. Clin Cancer Res. 2020 Apr 15;26(8):1820-1828. doi: 10.1158/1078-0432.CCR-19-2808. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937616
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.
Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Rodon J, et al. Mol Cancer Ther. 2008 Sep;7(9):2575-88. doi: 10.1158/1535-7163.MCT-08-0265. Mol Cancer Ther. 2008. PMID: 18790742 Free PMC article. Review.
Development of PARP inhibitors in oncology.
Rodon J, Iniesta MD, Papadopoulos K. Rodon J, et al. Expert Opin Investig Drugs. 2009 Jan;18(1):31-43. doi: 10.1517/13543780802525324. Expert Opin Investig Drugs. 2009. PMID: 19053880 Review.
Molecular basis for the treatment of renal cell carcinoma.
Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J. Suárez C, et al. Clin Transl Oncol. 2010 Jan;12(1):15-21. doi: 10.1007/s12094-010-0461-4. Clin Transl Oncol. 2010. PMID: 20080466 Review.
Combining targeted therapies: practical issues to consider at the bench and bedside.
Rodon J, Perez J, Kurzrock R. Rodon J, et al. Oncologist. 2010;15(1):37-50. doi: 10.1634/theoncologist.2009-0117. Epub 2010 Jan 15. Oncologist. 2010. PMID: 20080862 Free PMC article. Review.
TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.
Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn MM, Yingling JM, Rodón J, Sahuquillo J, Baselga J, Seoane J. Anido J, et al. Cancer Cell. 2010 Dec 14;18(6):655-68. doi: 10.1016/j.ccr.2010.10.023. Cancer Cell. 2010. PMID: 21156287
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.
Dienstmann R, Rodon J, Markman B, Tabernero J. Dienstmann R, et al. Recent Pat Anticancer Drug Discov. 2011 May;6(2):210-36. doi: 10.2174/157489211795328503. Recent Pat Anticancer Drug Discov. 2011. PMID: 21294710 Review.
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, Baselga J. Atzori F, et al. Clin Cancer Res. 2011 Oct 1;17(19):6304-12. doi: 10.1158/1078-0432.CCR-10-3336. Epub 2011 Aug 2. Clin Cancer Res. 2011. PMID: 21810918 Clinical Trial.
132 results
Jump to page
Feedback